Perioral Dermatitis and the Skin Barrier: A Corticosteroid-Adjacent Pathogenic Concept
Key Findings
- Topical corticosteroid use, including low-potency formulations, is among the most well-documented precipitating and perpetuating factors in perioral dermatitis.[1,2]
- Ljubojevic and Basta-Juzbasic's research characterizes a specific steroid-induced dermatitis subtype resembling rosacea, mechanistically and clinically relevant to perioral dermatitis.[3]
- The condition shows a well-documented paradox: corticosteroids can transiently improve appearance while perpetuating the underlying barrier disruption driving the condition.[1]
- Wollenberg et al.'s post-COVID-era review documents evolving understanding of exacerbating factors, including occlusive mask-related barrier stress.[8]
Have a clinical question?
Consult directly with our pharmacist.
Consult via WhatsAppPharm. Mine Ekber
The Corticosteroid-Barrier Disruption Cycle
Tempark and Shwayder's comprehensive review of perioral dermatitis identifies topical corticosteroid use — even low-potency formulations used for unrelated facial concerns — as among the most well-documented precipitating and perpetuating factors.[1] The mechanism involves a genuinely counterintuitive clinical trap: corticosteroids can transiently suppress visible inflammation, providing short-term improvement that encourages continued use, while the underlying barrier disruption and rebound inflammation mechanism continues to worsen with prolonged application — a self-perpetuating cycle requiring active clinical recognition to break.
Jansen and Plewig's Pathogenic Concept
Jansen and Plewig's specifically titled "pathogenic concept" work provides the mechanistic framework increasingly referenced in the perioral dermatitis literature: rather than a primary infectious or purely inflammatory process, the condition is understood as arising substantially from barrier disruption (frequently corticosteroid-induced) that permits a cascade of follicular and perifollicular inflammatory changes.[2]
Relationship to Steroid-Induced Rosacea-Like Dermatitis
Ljubojevic and Basta-Juzbasic's research on steroid dermatitis resembling rosacea documents a closely related, mechanistically overlapping condition, reinforcing that corticosteroid-induced barrier disruption can produce a spectrum of rosacea-adjacent and perioral dermatitis-pattern presentations rather than perioral dermatitis existing in complete clinical isolation.[3]
Barrier-Focused Management
Elias's barrier function research and Feingold and Elias's lipid formation and maintenance review together support the clinical management approach for perioral dermatitis: corticosteroid withdrawal (managed carefully given documented rebound flare risk) combined with barrier-supportive, low-irritant formulation rather than continued anti-inflammatory suppression that perpetuates the underlying cycle.[4,5] Buenger and Driller's research on ectoin's photoaging-prevention and cellular stress properties provides supporting rationale for barrier-gentle active ingredient selection during this recovery phase.[7]
Contemporary Exacerbating Factors
Wollenberg et al.'s post-COVID-era review documents an evolving understanding of exacerbating factors relevant to perioral dermatitis, including occlusive mask-related barrier stress — a contemporary environmental factor added to the traditional corticosteroid-centered pathogenic framework.[8] Bylka et al.'s Centella asiatica research provides supporting evidence for gentle, anti-inflammatory botanical support during the barrier-recovery phase of management.[6]
Conclusion
Perioral dermatitis' pathogenesis is distinctively tied to corticosteroid-induced barrier disruption, understood through Jansen and Plewig's pathogenic concept framework, supporting a management approach centered on careful corticosteroid withdrawal and barrier-supportive, low-irritant formulation rather than continued anti-inflammatory suppression. For a barrier-focused approach to perioral dermatitis management, our pharmacist, Mine Ekber, is available for direct consultation via WhatsApp.
Frequently Asked Questions
Can using a mild corticosteroid cream actually cause perioral dermatitis?
Yes — even low-potency topical corticosteroids are among the most well-documented precipitating and perpetuating factors for perioral dermatitis, through a barrier-disruption mechanism that can create a self-perpetuating cycle with continued use.
Why does perioral dermatitis sometimes get worse before it gets better?
This reflects the documented corticosteroid withdrawal rebound phenomenon, where stopping the perpetuating corticosteroid can produce a temporary flare before underlying barrier repair and inflammation resolution occurs, which is why careful, often clinically guided withdrawal is recommended.
Are masks a relevant factor in perioral dermatitis?
Contemporary post-COVID-era research has documented occlusive mask-related barrier stress as a relevant contemporary exacerbating factor, added to the traditional corticosteroid-centered understanding of the condition.
References
- Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol, 2014.
- Jansen T, Plewig G. Perioral dermatitis: a pathogenic concept. Hautarzt, 2011.
- Ljubojevic S, Basta-Juzbasic A. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol, 2005.
- Elias PM. Skin barrier function. Curr Allergy Asthma Rep, 2006.
- Feingold KR, Elias PM. Role of lipids in the formation and maintenance of the cutaneous permeability barrier. Biochim Biophys Acta, 2014.
- Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, Brzezińska M. Centella asiatica in cosmetology. Postepy Dermatol Alergol, 2020.
- Buenger J, Driller H. Ectoin: an effective natural substance to prevent UVA-induced premature photoaging. Skin Pharmacol Physiol, 2012.
- Wollenberg A, Szabo K, Oppel E, et al. Perioral dermatitis — a post-COVID era review of pathogenesis and treatment. J Dtsch Dermatol Ges, 2021.